Board Meeting8 Aug 2026, 03:50 pm
Ishita Drugs Board Approves Unaudited Q1 FY27 Results
AI Summary
Ishita Drugs & Industries Ltd announced that its Board of Directors met on August 8, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The board also approved the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director and accepted a revised remuneration proposal for Mr. Sumit Agrawal, the Chief Financial Officer. Additionally, the board discussed the ongoing upgradation project of the manufacturing facility, with approximately ₹435 lakh spent to date and capital contracts of about ₹565 lakh issued for utilities and equipment. The company is also in talks with banks to finance this project.
Key Highlights
- Unaudited financial results for Q1 FY27 approved.
- Re-appointment of a Non-Executive Director approved.
- Revised remuneration for CFO accepted.
- Manufacturing facility upgradation project is ongoing.
- Company is seeking funds for facility upgradation.
Price Impact
More from ISHITADR